CTNM Latest Press Releases

-- January 28, 2026 --

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- December 11, 2025 --

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering Business Wire 10:24 PM

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering Business Wire 4:05 PM

-- November 24, 2025 --

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference Business Wire 4:05 PM

-- November 20, 2025 --

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) Business Wire 4:05 PM

-- October 30, 2025 --

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Business Wire 4:05 PM

-- September 18, 2025 --

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 Business Wire 8:05 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software